Iranian Journal of War and Public Health

eISSN (English): 2980-969X
eISSN (Persian): 2008-2630
pISSN (Persian): 2008-2622
JMERC
0.3
Volume 14, Issue 2 (2022)                   Iran J War Public Health 2022, 14(2): 217-220 | Back to browse issues page

Print XML PDF HTML Full-Text (HTML)

History

How to cite this article
Umran Z, Abbas Hadi A, Mohammad A. Assessment of β-catenin as a Potential Marker for Human Colorectal Carcinoma. Iran J War Public Health 2022; 14 (2) :217-220
URL: http://ijwph.ir/article-1-1122-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rights and permissions
1- Department of Laboratory Investigations, Faculty of Science, University of Kufa, Najaf, Iraq
2- Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq
* Corresponding Author Address: Department of Pharmacology and therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq. Postal Code: 21 (ealkhazaaly@gmail.com)
Abstract   (746 Views)
Aims: Colorectal cancer was currently the most frequent malignant cancer of the gastrointestinal system, accounting for 13% of all malignant tumors, and it is the second most common cause of death from cancer worldwide. Aim of study was to clarify the relationship between β-catenin levels in sera, some clinical and pathological variables in Colorectal cancer patients, as well as explore the link between this biomarker and disease diagnosis and progression.
Material & Methods: The current study included (55) Colorectal cancer patients and (35) healthy subjects. ELISA was used to calculate serum β-catenin in order to study the relationships between this biomarker and gender, age, histological type, stages, grades, tumor site, and body mass index.
Findings: Results showed a significant increase in the levels of β-catenin of Colorectal cancer patients in comparison with the control group (p<0.05). In parallel, no significant correlations have been found in β-catenin levels with all clinical parameters covered by the study (p>0.05).
Conclusion: β-catenin is a less sensitive marker for Colorectal cancer in the detection and prognosis of the advanced stages of cancer.

 
Keywords:

References
1. American Cancer Society. Global cancer: facts and figures. Atlanta: American Cancer Society Report. 4th Edition; 2018. [Link]
2. Granados-Romero JJ, Valderrama-Treviño AI, Contreras-Flores EH, Barrera-Mera B, Enríquez MH, Uriarte-Ruíz K, et al. Colorectal cancer: a review. Int J Res Med Sci. 2017;5:4667-76. [Link] [DOI:10.18203/2320-6012.ijrms20174914]
3. Iraqi Cancer Board. Iraq cancer registry for 2018 report. Iraq: Ministry of Health and Environment; 2018. [Arabic] [Link]
4. Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci. 2020;21(15):5311. [Link] [DOI:10.3390/ijms21155311]
5. Willert K, Nusse R. Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev. 1998;8(1):95-102. [Link] [DOI:10.1016/S0959-437X(98)80068-3]
6. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192-205. [Link] [DOI:10.1016/j.cell.2012.05.012]
7. Lee WA. Prognostic significance of abnormal β-catenin expression in breast carcinoma. Korean J Pathol. 2005;39:114-9. [Link]
8. Lai TY, Su CC, Kuo WW, Yeh YL, Kuo WH, Tsai FJ, et al. β-catenin plays a key role in metastasis of human hepatocellular carcinoma. Oncol Rep. 2011;26(2):415-22. [Link]
9. Liu Z, Liu XW, Liu SA, Lv JJ, Fu Q. Clinical significance of changes of expression of the Wnt/β-catenin signaling pathway in renal clear cell carcinoma. Eur Rev Med Pharmacol Sci. 2016;20(23):4840-5. [Link]
10. Abdulrahman ZA, Ismael AT, Jalal JA, Alnuaimy WMT. Significance of B-catenin immunohistochemical expression in colorectal carcinoma. J Kurdistan Board of Med Specialties. 2018;4(1):51-6. [Link]
11. Li S, Huang M, Liu Q, Wang D, Wu R, Zhang X, et al. Serum expression of β-catenin is a potential detection marker in patients with colorectal cancer. Dis Mark. 2019;5070524. [Link] [DOI:10.1155/2019/5070524]
12. Yadav N, Ghalaut VS, Kumar S. Study of serum beta catenin levels in acute myeloid leukemia (AML) patients. Int J Adv Res. 2020;8(03):188-94. [Link] [DOI:10.21474/IJAR01/10615]
13. Gunes BA, Ozkan T, Gurel AK, Hekmatshoar Y, Beksac M, Sunguroglu A. β-catenin mutations in acute myeloid leukemia. Egyp J Haematol. 2020;45(2):105-10. [Link] [DOI:10.4103/ejh.ejh_54_19]
14. Zekri AR, Bahnassy AA, Alam El-Din HM, Morsy HM, Shaarawy S, et al. Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncol Rep. 2011;26(4):825-31. [Link]
15. Yoshida N, Kinugasa T, Ohshima K, Yuge K, Ohchi T, Fujino S, et al. Analysis of Wnt and β-catenin expression in advanced colorectal cancer. Anticancer Res. 2015;35(8):4403-10. [Link]
16. Wangefjord S, Brändstedt J, Lindquist KE, Nodin B, Jirström K, Eberhard J. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol. 2013;8:10. [Link] [DOI:10.1186/1746-1596-8-10]
17. Suzuki H, Masuda N, Shimura, T, Araki K, Kobayashi T, Tsutsumi S, et al. Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res. 2008;28(3B):1821-30. [Link]
18. Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med. 2016;14(21):1-12. [Link] [DOI:10.1186/s12967-016-0772-5]

Add your comments about this article : Your username or Email:
CAPTCHA